Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.
暂无分享,去创建一个
Y. Tsai | Hyung-Suk Kim | N. Maeda | Jason K. Kim | N. Takahashi | Hyo-Jeong Kim | Nobuyuki Takahashi | Hyung-Suk Kim | J. Hagaman | Hyo-Jeong Kim | Jason K Kim | Nobuyo Maeda | Yau-Sheng Tsai | John R Hagaman
[1] T. Coffman,et al. Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. , 2000, Hypertension.
[2] J. Hodgin,et al. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.
[3] G. Williams,et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. , 1999, Diabetes.
[4] Young-Bum Kim,et al. Uncoupling Protein-2 Negatively Regulates Insulin Secretion and Is a Major Link between Obesity, β Cell Dysfunction, and Type 2 Diabetes , 2001, Cell.
[5] S. O’Rahilly,et al. The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.
[6] C. Kahn,et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. , 2000, The Journal of clinical investigation.
[7] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[8] HiroakiMatsubara. Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases , 1998 .
[9] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[10] B. Lowell,et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. , 2001, Cell.
[11] S. O’Rahilly,et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.
[12] Jimmy D Bell,et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.
[13] Johan Auwerx,et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.
[14] J. Greer,et al. Targeting genes for self-excision in the germ line. , 1999, Genes & development.
[15] R. Evans,et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.
[16] B. Staels,et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.
[17] N. Maeda,et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[18] Tianxin Yang,et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. , 1999, American journal of physiology. Renal physiology.
[19] Satoshi Tanaka,et al. PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .
[20] P. Libby,et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.
[21] S. O’Rahilly,et al. Digenic inheritance of severe insulin resistance in a human pedigree , 2002, Nature Genetics.
[22] P. Libby,et al. PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .
[23] A. Garg,et al. A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .
[24] E. Furth,et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. , 2001, Nature medicine.
[25] R. Burcelin,et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.
[26] D. Scott,et al. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. , 2001, Biochimie.
[27] C. Kahn,et al. Impact of genetic background on development of hyperinsulinemia and diabetes in insulin receptor/insulin receptor substrate-1 double heterozygous mice. , 2003, Diabetes.
[28] A. Schäffer,et al. Genetic modifiers of the insulin resistance phenotype in mice. , 2000, Diabetes.
[29] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[30] Y. Terauchi,et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.
[31] S. O’Rahilly,et al. Depot-related gene expression in human subcutaneous and omental adipocytes. , 1998, Diabetes.
[32] Y. Deshaies,et al. PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. , 2003, Diabetes.
[33] M. Lean,et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.
[34] P. Libby,et al. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[35] R. Evans,et al. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. , 2000, The Journal of clinical investigation.
[36] B. Egan,et al. Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.
[37] J. Stamler,et al. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. , 1978, JAMA.
[38] J. Hoofnagle,et al. Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.
[39] P. Ferré,et al. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. , 2002, American journal of physiology. Endocrinology and metabolism.
[40] I. Gabriely,et al. Differential Gene Expression Between Visceral and Subcutaneous Fat Depots , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[41] R. Evans,et al. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .
[42] S. Aizawa,et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. , 1999, Molecular cell.
[43] T. Ogihara,et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. , 1995, American journal of hypertension.
[44] R. Davisson,et al. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. , 2001, Physiological genomics.
[45] A. Medvedev,et al. Transcriptional Regulation of the Mouse Uncoupling Protein-2 Gene , 2001, The Journal of Biological Chemistry.
[46] A. Pfeiffer,et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.
[47] K. Chien,et al. PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .
[48] H. Uozumi,et al. Peroxisome Proliferator-Activated Receptor γ Plays a Critical Role in Inhibition of Cardiac Hypertrophy In Vitro and In Vivo , 2002 .
[49] R. Scott. Weight and Blood Pressure , 1948, British medical journal.
[50] S. Engeli,et al. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. , 2000, Hypertension.
[51] A. Fukamizu,et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] S. Kiechl,et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. , 1998, Diabetes.
[53] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.
[54] R. Hegele,et al. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. , 2002, Diabetes.
[55] T. Kotchen,et al. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. , 1993, The American journal of physiology.
[56] P. Weidmann,et al. Insulin, insulin sensitivity and hypertension. , 1990, Journal of hypertension.
[57] K. Takeda,et al. Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells , 2000 .